Consistently, endometrial cancers have wild-type ARID1A in the primary tumors, whereas the metastatic subclones carry deleterious mutations, further indicating context-dependent function of ARID1A in primary versus metastatic cancers [41]. Here, ARID1A is linked to endometrial cancer.